Connor, Clark & Lunn Investment Management (CC&L)’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio DCPH Stock Details DCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-279,047	Closed	-$4.39M	–	1761
2024 Q1	$4.39M	Buy	279,047 +27,902	+11%	+$429K	0.02%	463
2023 Q4	$4.05M	Buy	251,145 +178,973	+248%	+$2.28M	0.02%	489
2023 Q3	$918K	Buy	72,172 +6,296	+10%	+$86.9K	﹤0.01%	846
2023 Q2	$928K	Buy	65,876 +49,989	+315%	+$715K	﹤0.01%	816
2023 Q1	$245K	Buy	+15,887	New	+$265K	﹤0.01%	1050
2022 Q2	–	Sell	-89,885	Closed	-$833K	–	1228
2022 Q1	$833K	Buy	89,885 +52,757	+142%	+$449K	﹤0.01%	695
2021 Q4	$363K	Buy	+37,128	New	+$698K	﹤0.01%	864

Other funds holding DCPH

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s DCPH Position: Q2 2024 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 279,047 shares — an estimated $4.39M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in DCPH in Q4 2021 and held it in 7 quarters. The position peaked at $4.39M in Q1 2024. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 279,047 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $4.39M.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $4.39M in Q1 2024.
1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2024, filed 9 Aug 2024.